Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly
- PMID: 17675523
- DOI: 10.4049/jimmunol.179.4.2600
Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly
Abstract
Complement promotes the rapid recognition and elimination of pathogens, infected cells, and immune complexes. The biochemical basis for its target specificity is incompletely understood. In this report, we demonstrate that properdin can directly bind to microbial targets and provide a platform for the in situ assembly and function of the alternative pathway C3 convertases. This mechanism differs from the standard model wherein nascent C3b generated in the fluid phase attaches nonspecifically to its targets. Properdin-directed complement activation occurred on yeast cell walls (zymosan) and Neisseria gonorrhoeae. Properdin did not bind wild-type Escherichia coli, but it readily bound E. coli LPS mutants, and the properdin-binding capacity of each strain correlated with its respective serum-dependent AP activation rate. Moreover, properdin:single-chain Ab constructs were used to direct serum-dependent complement activation to novel targets. We conclude properdin participates in two distinct complement activation pathways: one that occurs by the standard model and one that proceeds by the properdin-directed model. The properdin-directed model is consistent with a proposal made by Pillemer and his colleagues >50 years ago.
Similar articles
-
An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae.J Immunol. 2010 Jul 1;185(1):507-16. doi: 10.4049/jimmunol.0903598. Epub 2010 Jun 7. J Immunol. 2010. PMID: 20530262 Free PMC article.
-
Activation of the alternative pathway of human complement by autologous cells expressing transmembrane recombinant properdin.Mol Immunol. 2000 Jun;37(8):467-78. doi: 10.1016/s0161-5890(00)00069-9. Mol Immunol. 2000. PMID: 11090881
-
Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement.Blood. 2008 Jan 15;111(2):732-40. doi: 10.1182/blood-2007-05-089821. Epub 2007 Oct 4. Blood. 2008. PMID: 17916747 Free PMC article.
-
Properdin and complement activation: a fresh perspective.Curr Drug Targets. 2008 Feb;9(2):158-64. doi: 10.2174/138945008783502458. Curr Drug Targets. 2008. PMID: 18288967 Review.
-
Properdin: New roles in pattern recognition and target clearance.Mol Immunol. 2008 Oct;45(16):4048-56. doi: 10.1016/j.molimm.2008.06.034. Epub 2008 Aug 8. Mol Immunol. 2008. PMID: 18692243 Free PMC article. Review.
Cited by
-
Complement-targeted therapeutics in periodontitis.Adv Exp Med Biol. 2013;735:197-206. doi: 10.1007/978-1-4614-4118-2_13. Adv Exp Med Biol. 2013. PMID: 23402028 Free PMC article. Review.
-
Complement in Tumourigenesis and the Response to Cancer Therapy.Cancers (Basel). 2021 Mar 10;13(6):1209. doi: 10.3390/cancers13061209. Cancers (Basel). 2021. PMID: 33802004 Free PMC article. Review.
-
Role of complement in host-microbe homeostasis of the periodontium.Semin Immunol. 2013 Feb;25(1):65-72. doi: 10.1016/j.smim.2013.04.004. Epub 2013 May 16. Semin Immunol. 2013. PMID: 23684627 Free PMC article. Review.
-
Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury.J Clin Invest. 2010 Oct;120(10):3545-54. doi: 10.1172/jci41782. J Clin Invest. 2010. PMID: 20941861 Free PMC article.
-
Chimeric Proteins Containing MAP-1 and Functional Domains of C4b-Binding Protein Reveal Strong Complement Inhibitory Capacities.Front Immunol. 2018 Aug 28;9:1945. doi: 10.3389/fimmu.2018.01945. eCollection 2018. Front Immunol. 2018. PMID: 30210498 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous